LEXARIA BIOSCIENCE CORP. Financing Receivable, after Allowance for Credit Loss
LEXARIA BIOSCIENCE CORP. (LEXX) had Financing Receivable, after Allowance for Credit Loss of $2.00 million as of 2024-08-31, per its 10-K filed 2024-11-26.
Financial Statements › Balance Sheet › Assets
us-gaap:NotesReceivableNet · last filed 2024-11-26
- 2024-08-31: Financing Receivable, after Allowance for Credit Loss $2.00M.
- 2023-08-31: Financing Receivable, after Allowance for Credit Loss $2.00M.
| Period end | Financing Receivable, after Allowance for Credit Loss |
|---|---|
| 2024-08-31 | $2.00M 10-K · filed 2024-11-26 |
| 2023-08-31 | $2.00M 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |